research Successful etanercept therapy in therapy refractory acrodermatitis continua suppurativa Hallopeau
Etanercept effectively treated a severe skin condition when other treatments failed.
Search
for
Sort by
Research
300-330 / 1000+ results
research Cutaneous toxicities of new targeted cancer therapies: must know for diagnosis, management, and patient-proxy empowerment
New targeted cancer drugs can cause skin side effects, and managing them requires patient education and timely care.
research Alopecia Areata: Hair and Nail Findings in a Patient Undergoing Talquetamab Therapy for Multiple Myeloma
Talquetamab may cause hair loss and skin issues.
research Fluorouracil-Induced Reactive Follicular Squamous Cell Carcinoma
research Dupilumab treatment for atopic dermatitis leading to unexpected treatment for alopecia universalis
A medication for skin rash also unexpectedly treated hair loss in a patient.
research Assessment of hair loss and skin changes during treatment in Asian breast cancer patients: A prospective cohort study
Taxane-based chemotherapy causes more hair loss and skin changes in Asian breast cancer patients.
research First-in-human phase 1 study of ETC-159 an oral PORCN inhbitor in patients with advanced solid tumours.
ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.
research Abstract P5-09-21: Selective androgen receptor modulators (SARMs): Enobosarm as targeted therapy for the treatment of androgen receptor-positive breast cancer
Enobosarm may effectively treat androgen receptor-positive breast cancer with fewer side effects.
research Vorasidenib-Induced Trichomegaly and Hypertrichosis: a New Side Effect in a Patient with Diffuse Astrocytoma
Vorasidenib can cause unusual hair growth.
research Persistent hair growth during treatment with the EGFR inhibitor erlotinib
Erlotinib can cause persistent excessive hair growth.
research Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients.
BRAF inhibitors for melanoma often cause skin side effects, but they can be managed with proper care.
research Kinase Inhibition with BAY 43–9006 in Renal Cell Carcinoma
BAY 43-9006 helps control kidney cancer growth but doesn't significantly increase overall survival.
research Unusual progression of renal cell carcinoma with carcinomatosis peritoneii and Krukenberg tumour and alopecia with sunitinib therapy in young female
A young woman with kidney cancer experienced rare hair loss from a cancer drug and unusual cancer spread, suggesting early drug treatment might reduce spread and prolong survival.
research 699 Pharmacological blockade of the CX3CR1/CX3CL1 fractalkine axis prevents alopecia areata in C3H/HeJ mice
research CDK4/6 plus aromatase inhibitor-induced alopecia in breast cancer patients.
Some breast cancer treatments cause hair loss similar to male pattern baldness, which can be improved with minoxidil.
research 576 INTASYL PH-762: Intratumoral immunotherapy targeting PD-1
PH-762 shows promise in treating skin cancer by effectively targeting and silencing PD-1 in tumors with minimal side effects.
research Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)
BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.
research Ruxolitinib protects skin stem cells and maintains skin homeostasis in murine graft-versus-host disease
Ruxolitinib helps protect skin stem cells and keeps skin healthy in mice with skin GVHD.
research Ruxolitinib for the treatment of severe alopecia areata
Ruxolitinib can help regrow hair in severe alopecia areata.
research Biological therapy in the treatment of melanoma
Biological therapy boosts the immune system to effectively fight melanoma.
research PRIDE syndrome with lumbosacral hypertrichosis
EGFR inhibitors can cause unusual localized hair growth.
research Delayed granulomatous eruption of the nose associated with ruxolitinib
Ruxolitinib can cause a delayed skin reaction on the nose.
research Analysis of changes in microRNA expression profiles in response to the troxerutin-mediated antioxidant effect in human dermal papilla cells
research 0478 Outcomes of oral dutasteride and oral minoxidil for treating endocrine therapy-induced alopecia from breast cancer treatment: A case series
research Use of a Healthcare Claims Database for Post-Marketing Safety Assessments of Eribulin in Japan: A Comparative Assessment with a Prospective Post-Marketing Surveillance Study
Healthcare claims databases can help monitor drug safety, but may report adverse events differently than direct surveillance.
research Moving Beyond Boundaries: Utilization of Longitudinal Exposure–Response Model for Bounded Outcome Score to Inform Decision Making in the Accelerated Drug Development Paradigm
A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.
research Association of prior 5-α-reductase inhibitor exposure with ICI benefit in metastatic RCC: Multicentre cohort with single-cell immune profiling.
Using 5-α-reductase inhibitors before treatment improves outcomes for patients with metastatic renal cell carcinoma.
research Haarwachstum unter Dupilumab bei Alopecia areata universalis und atopischer Dermatitis
Dupilumab can help regrow hair and improve skin conditions in patients with severe atopic dermatitis and alopecia areata.
![2-Deoxy-2-[18F]Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography](/images/research/35fab163-57b7-4db8-b1e0-2929b51b2144/small/60162.jpg)
research 2-Deoxy-2-[18F]fluoro-D-Glucose Positronen-Emissions-Tomographie/Computertomographie
FDG PET/CT can improve cancer treatment plans in dogs.
research Dermatologic Reactions to Targeted Therapy
Targeted cancer therapies can cause skin side effects, which should be treated early to help patients' quality of life and treatment adherence.